Get started
Author

Veerandra Kumar

Observed name: V. Kumar
ORCID: 0009-0003-7448-7560
Observed ORCID: 0009-0003-7448-7560
OpenAlex ID: A5004406532
Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review
2021 · Priyanka Singh, Veerandra Kumar, et al. · Medical Oncology · 63
Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review
2022 · Veerandra Kumar, Priyanka Singh, et al. · Molecular and Cellular Biochemistry · 44
Developing therapeutic approaches for chronic myeloid leukemia: a review
2022 · Veerandra Kumar, Jyotirmayee, et al. · Molecular and Cellular Biochemistry · 9
Alterations in cellular metabolisms after Imatinib therapy: a review
2022 · Veerandra Kumar, Priyanka Singh, et al. · Medical Oncology · 8
Naringin: a novel anticancer candidate against chemically induced hepatocellular carcinoma in rats
2017 · V. Kumar, A. Verma · European Journal of Cancer · 2
From pumps to networks: ABC transporters in leukemia resistance and microenvironmental adaptation
2026 · Jyotirmayee, Veerandra Kumar, et al. · Medical Oncology
Recent trends in drug delivery systems: Lymphatic drug targeting and transportation
1999 · Jayanth Panyam, Veerandra Kumar, et al.
Works count: 7
Citation count: 126
H-index: 4
I10-index: 2
Year
Topic
Type